Abstract
Current psychiatric diagnoses are not defined by neurobiological measures which hinders the development of therapies targeting mechanisms underlying mental illness 1,2. Research confined to diagnostic boundaries yields heterogeneous biological results, whereas transdiagnostic studies often investigate individual symptoms in isolation. There is currently no paradigm available to comprehensively investigate the relationship between different clinical symptoms, individual disorders, and the underlying neurobiological mechanisms. Here, we propose a framework that groups clinical symptoms derived from ICD-10/DSM-V according to shared brain mechanisms defined by brain structure, function, and connectivity. The reassembly of existing ICD-10/DSM-5 symptoms reveal six cross-diagnostic psychopathology scores related to mania symptoms, depressive symptoms, anxiety symptoms, stress symptoms, eating pathology, and fear symptoms. They were consistently associated with multimodal neuroimaging components in the training sample of young adults aged 23, the independent test sample aged 23, participants aged 14 and 19 years, and in psychiatric patients. The identification of symptom groups of mental illness robustly defined by precisely characterized brain mechanisms enables the development of a psychiatric nosology based upon quantifiable neurobiological measures. As the identified symptom groups align well with existing diagnostic categories, our framework is directly applicable to clinical research and patient care.
Competing Interest Statement
Dr. Banaschewski served in an advisory or consultancy role for Lundbeck, Medice, Neurim Pharmaceuticals, Oberberg GmbH, Shire. He received conference support or speaker's fee from Lilly, Medice, Novartis and Shire. He has been involved in clinical trials conducted by Shire & Viforpharma. He received royalties from Hogrefe, Kohlhammer, CIP Medien, Oxford University Press. The present work is unrelated to the above grants and relationships. Dr. Poustka served in an advisory or consultancy role for Roche and Viforpharm and received a speaker's fee from Shire. She received royalties from Hogrefe, Kohlhammer and Schattauer. The present work is unrelated to the above grants and relationships. The other authors report no biomedical financial interests or potential conflicts of interest.
Funding Statement
This work received support from the following sources: the European Union-funded Horizon Europe project environMENTAL (101057429) and co-funding by UK Research and Innovation under the UK Government's Horizon Europe funding guarantee (10041392 and 10038599); the Horizon 2020-funded European Research Council Advanced Grant 'STRATIFY' (695313); the German Research Foundation (COPE; 675346); the European Union-funded FP6 Integrated Project IMAGEN (Reinforcement-related behaviour in normal brain function and psychopathology) (LSHM-CT-2007-037286), the Medical Research Council and Medical Research Foundation (grants MR/R00465X/1 and MRF-058-0004-RG-DESRI: 'ESTRA: Neurobiological underpinning of eating disorders: integrative biopsychosocial longitudinal analyses in adolescents/; MR/S020306/1 and MRF-058-0009-RG-DESR-C0759: 'Establishing causal relationships between biopsychosocial predictors and correlates of eating disorders and their mediation by neural pathways') the Medical Research Council (grant MR/W002418/1: 'Eating Disorders: Delineating illness and recovery trajectories to inform personalized prevention and early intervention in young people (EDIFY)' and the National Institute for Health and Research (NIHR) Biomedical Research Centre (BRC) and Maudsley NHS Foundation Trust (SLaM). The Human Brain Project (HBP SGA 2, 785907, and HBP SGA 3, 945539), the National Key R&D Program of Ministry of Science and Technology of China (MOST 2023YFE0199700). The Medical Research Council Grant 'c-VEDA' (Consortium on Vulnerability to Externalizing Disorders and Addictions) (MR/N000390/1), the National Institute of Health (NIH) (R01DA049238, A decentralized macro and micro gene-by-environment interaction analysis of substance use behavior and its brain biomarkers), the Bundesministerium fur Bildung und Forschung (BMBF grants 01GS08152; 01EV0711; Forschungsnetz AERIAL 01EE1406A, 01EE1406B; Forschungsnetz IMAC-Mind 01GL1745B), the Medical Research Foundation (MRF-058-0014-F-ZHAN-C0866) and the National Institutes of Health (NIH) funded ENIGMA (grants 5U54EB020403-05 and 1R56AG058854-01), NSFC grant (82150710554).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IMAGEN data are available from a dedicated database at https://imagen-project.org. STRATIFY/ESTRA data are available from the STRATIFY/ESTRA database at https://stratify-project.org.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
